Merck: FDA Rejects Gefapixant Application, Requests More Data

Merck & Co. on Monday said the U.S. Food and Drug Administration has turned away the drugmaker's application seeking approval of gefapixant for the treatment of refractory chronic cough or unexplained chronic cough in adults, and the agency is seeking additional information.